KIN - Kindred Biosciences, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.71
-0.18 (-2.61%)
As of 1:07PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close6.89
Open6.86
Bid6.71 x 1000
Ask6.72 x 900
Day's Range6.70 - 6.88
52 Week Range6.62 - 15.75
Volume112,170
Avg. Volume165,111
Market Cap261.724M
Beta (3Y Monthly)0.25
PE Ratio (TTM)N/A
EPS (TTM)-1.67
Earnings DateAug 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.81
Trade prices are not sourced from all markets
  • PR Newswire2 days ago

    Kindred Biosciences to Announce Second Quarter 2019 Financial Results

    SAN FRANCISCO, July 16, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will release its second quarter 2019 financial results on August 1, 2019, after the market close. The Company will host a conference call at 4:30 p.m. Eastern time/1:30 p.m. Pacific time that day. Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets.

  • Here’s What Hedge Funds Think About Kindred Biosciences Inc (KIN)
    Insider Monkey20 days ago

    Here’s What Hedge Funds Think About Kindred Biosciences Inc (KIN)

    Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 20 stocks among hedge funds beat the S&P […]

  • TheStreet.com27 days ago

    A Handful of Small Biotechs That Make for Merger Chatter

    The biotech sector continues to have a very good week, although some profit taking did take place in the second half of trading Thursday even as the S&P 500 hit an all-time high. On Wednesday we considered a couple mid-cap biotech names that would make logical buyout candidates should we see an uptick in merger-and-acquisition (M&A) activity in the second half of the year. Kindred has just one approved product but several in development.

  • PR Newswire2 months ago

    Kindred Biosciences to Participate in the B. Riley FBR Institutional Investor Conference, Stifel 2019 Dental & Veterinary Conference and 9th Annual LD Micro Invitational

    SAN FRANCISCO , May 13, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will participate in ...

  • Kindred Biosciences (KIN) Q1 2019 Earnings Call Transcript
    Motley Fool2 months ago

    Kindred Biosciences (KIN) Q1 2019 Earnings Call Transcript

    KIN earnings call for the period ending March 31, 2019.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of KIN earnings conference call or presentation 9-May-19 8:30pm GMT

    Q1 2019 Kindred Biosciences Inc Earnings Call

  • Kindred Biosciences (KIN) Reports Q1 Loss, Misses Revenue Estimates
    Zacks2 months ago

    Kindred Biosciences (KIN) Reports Q1 Loss, Misses Revenue Estimates

    Kindred Bio (KIN) delivered earnings and revenue surprises of 0.00% and -73.62%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Kindred Bio: 1Q Earnings Snapshot

    On a per-share basis, the Burlingame, California-based company said it had a loss of 42 cents. The biopharmaceutical company posted revenue of $515,000 in the period. Kindred Bio shares have dropped 18% ...

  • PR Newswire2 months ago

    Kindred Biosciences Announces First Quarter 2019 Financial Results

    SAN FRANCISCO, May 9, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the first quarter ended March 31, 2019 and provided updates on its programs. For the first quarter 2019, KindredBio reported net product revenues of $0.5 million and a net loss of $16.1 million, or $0.42 per share. While net product revenues were lower versus the fourth quarter, sales of Mirataz from distributors to veterinary clinics increased quarter-over-quarter.

  • Do Institutions Own Kindred Biosciences, Inc. (NASDAQ:KIN) Shares?
    Simply Wall St.2 months ago

    Do Institutions Own Kindred Biosciences, Inc. (NASDAQ:KIN) Shares?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The big shareholder groups in Kindred Biosciences, Inc. (NASDAQ:KIN) have power over the company...

  • PR Newswire3 months ago

    Kindred Biosciences to Announce First Quarter 2019 Financial Results

    SAN FRANCISCO, April 25, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will release its first quarter 2019 financial results on May 9, 2019 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time that day. Kindred Biosciences is a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets.

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of KIN earnings conference call or presentation 6-Mar-19 9:30pm GMT

    Q4 2018 Kindred Biosciences Inc Earnings Call

  • Kindred Biosciences, Inc. (NASDAQ:KIN) Has Attractive Fundamentals
    Simply Wall St.4 months ago

    Kindred Biosciences, Inc. (NASDAQ:KIN) Has Attractive Fundamentals

    Kindred Biosciences, Inc. (NASDAQ:KIN) is a company with exceptional fundamental characteristics. Upon building up an investment case for a stock, we should look at various aspects. In the case ofRead More...

  • Kindred Biosciences Inc (KIN) Q4 2018 Earnings Conference Call Transcript
    Motley Fool4 months ago

    Kindred Biosciences Inc (KIN) Q4 2018 Earnings Conference Call Transcript

    KIN earnings call for the period ending December 31, 2018.

  • PR Newswire4 months ago

    Kindred Biosciences Announces Fourth Quarter and Full Year 2018 Financial Results

    SAN FRANCISCO, March 6, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced financial results for the fourth quarter and full year ended December 31, 2018 and provided updates on its programs. For the fourth quarter 2018, KindredBio reported net product revenues of $1.3 million and a net loss of $15.4 million, or $0.46 per share. For the full year 2018, net product revenues were $2.0 million and the net loss was $49.7 million, or $1.60 per share.

  • PR Newswire5 months ago

    Kindred Biosciences to Announce Fourth Quarter and Year-End 2018 Financial Results

    Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on Wednesday, March 6, 2019 SAN FRANCISCO , Feb. 19, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: ...

  • PR Newswire5 months ago

    Kindred Biosciences to Present at Bank of America Merrill Lynch Animal Health Summit and Barclays Global Healthcare Conference

    SAN FRANCISCO , Feb. 13, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, will present at the ...

  • PR Newswire5 months ago

    Kindred Group plc - Year end report January - December 2018 (Unaudited)

    Underlying EBITDA for the fourth quarter of 2018 was GBP 58.8 (74.5) million, and GBP 203.7 (185.0) million for the full year 2018. Profit before tax for the fourth quarter of 2018 amounted to GBP 45.0 (55.9) million, and GBP 149.5 (132.0) million for the full year 2018.

  • PR Newswire6 months ago

    Kindred Biosciences Announces Closing of Public Offering of Common Stock and the Full Exercise of Underwriters' Option to Purchase Additional Shares

    SAN FRANCISCO, Jan. 23, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, announced that it has closed its public offering of 4,847,250 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase 632,250 additional shares of KindredBio's common stock, at $9.50 per share, less underwriting discounts and commissions. Barclays Capital Inc. and Stifel acted as joint book-running managers. A.G.P. / Alliance Global Partners and H.C. Wainwright & Co. provided financial advisory services.

  • PR Newswire6 months ago

    Kindred Biosciences Named Best Company in North America by Leading Industry Publication

    SAN FRANCISCO, Jan. 22, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced that it has been named Best Company in North America by Animal Pharm, a leading industry publication. In announcing the honor, Animal Pharm noted KindredBio's transition to a commercial-stage firm in 2018 with the approval of Mirataz® (mirtazapine transdermal ointment) for the management of weight loss in cats.

  • PR Newswire6 months ago

    Kindred Biosciences Announces Pricing of Public Offering

    SAN FRANCISCO, Jan. 18, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of an underwritten public offering of 4,215,000 shares of its common stock at a public offering price of $9.50 per share, for a total offering amount of $40,042,500 before deducting underwriting discounts and commissions and estimated offering expenses payable by KindredBio.  KindredBio has granted to the underwriters a 30-day option to purchase up to an additional 632,250 shares of its common stock on the same terms and conditions. Barclays Capital Inc. and Stifel are acting as joint book-running managers. A.G.P. / Alliance Global Partners and H.C. Wainwright & Co. provided financial advisory services.

  • PR Newswire6 months ago

    Kindred Biosciences Announces Proposed Public Offering of Common Stock

    SAN FRANCISCO, Jan. 17, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial stage biopharmaceutical company focused on saving and improving the lives of pets, today announced a proposed public offering of its common stock. All of the common stock is being offered by KindredBio. In addition, KindredBio intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions.

  • PR Newswire6 months ago

    Kindred Biosciences Announces Positive Results from Pilot Field Effectiveness Study of epoCat™ for the Management of Non-Regenerative Anemia in Cats and Availability of Mirataz® at Banfield Pet Hospital

    SAN FRANCISCO, Jan. 14, 2019 /PRNewswire/ -- Kindred Biosciences, Inc. (KIN), a commercial-stage biopharmaceutical company focused on saving and improving the lives of pets, today announced positive topline results from its pilot field effectiveness study of epoCat (KIND-510a), a long-acting feline recombinant erythropoietin that is being developed for the management of anemia in cats. In the study, which enrolled 23 cats with anemia, epoCat rapidly increased mean hematocrit (a measure of red blood cell count), with statistically significant improvement seen as early as Week 1 (p

  • Bringing world class medication to animals
    Yahoo Finance Video6 months ago

    Bringing world class medication to animals

    KindredBio is a company focused on bringing ground-breaking human products and innovative new technologies to veterinary medicine. Yahoo Finance's Adam Shapiro and Brian Sozzi discuss with company founder & CEO, Richard Chin, along with its founder and president, Denise Bevers.